Drugs used | Patients n | Outcome | Treatment# duration days |
AmB-d | 24 | 22 D/2 S | 1–25/NA |
AmB-d + inhaled AmB-d | 1 | S | 75 |
AmB-d + instillation of AmB-d | 1 | D | NA |
AmB-d + 5FC | 2 | 2 D | NA |
AmB-d + ITZ | 6 | 6 D | 3–14 |
AmB-d + ITZ + GM-CSF | 2 | 2 D | 17–23 |
AmB-d followed by ABLC | 5 | 5 D | NA |
ITZ followed by AmB-d | 1 | D | 6 |
Fluconazole followed by AmB-d | 1 | D | 10 |
No treatment | 13 | 13 D |
Data from 12, 13, 34, 36, 37, 39–54. AmB-d: Amphotericin B deoxycholate; D: death; S: survival; NA: not available; 5FC: 5-fluorocytosine; ITZ: itraconazole; GM-CSF: granulocyte-macrophage colony-stimulating factor; ABLC: amphotericin B lipid complex. #: Intravenous AmBd was administered at a daily dose of 0.1–1.3 mg·kg−1 (data available in 25 patients) and ABLC at 5 mg·kg−1·day−1.